Gillian Barth is a dedicated PhD candidate at Purdue University, specializing in molecular pharmacy and protein biology, with a keen focus on drug development. Her current research is pivotal in addressing the challenges posed by drug-resistant pathogens, particularly Staphylococcus aureus and Enterococcus faecalis. Through her...
Gillian Barth is a dedicated PhD candidate at Purdue University, specializing in molecular pharmacy and protein biology, with a keen focus on drug development. Her current research is pivotal in addressing the challenges posed by drug-resistant pathogens, particularly Staphylococcus aureus and Enterococcus faecalis. Through her dissertation, Gillian is investigating the mevalonate pathway, a critical metabolic route that has implications for antibiotic resistance. She has identified the fatty acid synthesis protein FabD as a promising secondary target for novel inhibitors, employing advanced techniques such as thermal shift screening to measure binding affinities and utilizing X-ray crystallography to elucidate the structures of inhibitor-bound complexes.
Gillian’s expertise extends beyond her research; she is proficient in protein-protein interactions and enzyme kinetics, which are essential for understanding the dynamics of drug-target engagement. Her skills in polymerase chain reaction (PCR) and laboratory animal medicine further enhance her capabilities in experimental design and execution. In addition to her technical acumen, Gillian demonstrates strong communication and management skills, which she applies as an instructor and during scientific outreach initiatives. She is passionate about promoting scientific literacy and fostering a deeper understanding of molecular pharmacy among diverse audiences. Through her multifaceted role at Purdue University, Gillian Barth is not only contributing to the advancement of drug discovery but also inspiring the next generation of scientists in the field of pharmaceutical research.
